Targeting Macrophages in Glioblastoma Offers Promising Therapeutic Strategy

Glioblastoma, an aggressive brain tumor, is characterized by an immunosuppressive tumor microenvironment that contributes to treatment resistance and disease progression. Research has identified tumor-associated macrophages, comprising both resident microglia and bone marrow-derived macrophages, as a central component in supporting tumor growth, angiogenesis, and immune evasion. A systematic literature review and analysis of 30 studies on therapeutic approaches targeting tumor-associated macrophages (TAMs) in glioblastoma have shed light on the potential for targeting TAMs as a multifaceted strategy for GBM treatment.

Key Takeaways:

• Research has identified tumor-associated macrophages (TAMs) as a key component in supporting tumor growth, angiogenesis, and immune evasion in glioblastoma (GBM).
• A systematic literature review and analysis of 30 studies on therapeutic approaches targeting TAMs in GBM have identified three main strategies: inhibition of TAM recruitment, enhancement of TAM-mediated phagocytosis, and reprogramming of TAMs.
• Combination strategies, including TAM-targeting with checkpoint inhibitors, nanoparticles, and oncolytic viruses, show synergistic effects in preclinical models.
• Targeting TAMs represents a multifaceted strategy for GBM treatment, with current evidence underscoring the need for combination approaches integrating TAM modulation with existing standard-of-care therapies.
• Clinical translation is limited due to challenges such as TAM heterogeneity, plasticity, immunosuppressive therapies, and restricted drug delivery across the blood-brain barrier.
• Future directions should highlight personalized treatments based on detailed TME profiling, combining TAM-targeted therapies with agents modulating metabolic or immune pathways, and leveraging advanced delivery systems and spatial transcriptomics.
• Researchers from Fondazione Policlinico Universitario A. Gemelli IRCCS, including Federico Valeri, Giovanni Pennisi, Benedetta Burattini, and others, have made significant contributions to the understanding of targeting TAMs in glioblastoma.

Statistics:

• 30 studies on therapeutic approaches targeting tumor-associated macrophages (TAMs) in glioblastoma were included in the systematic literature review.
• 3 main strategies for targeting TAMs in GBM were identified: inhibition of TAM recruitment, enhancement of TAM-mediated phagocytosis, and reprogramming of TAMs.
• Combination strategies showed synergistic effects in preclinical models, with a combination of TAM-targeting with checkpoint inhibitors, nanoparticles, and oncolytic viruses yielding improved efficacy.
• 165 cancer patients are addressed by this current study.

Sources:

• NewsRx. Studies from Fondazione Policlinico Universitario A. Gemelli IRCCS Further Understanding of Cancer Gene Therapy (Targeting Macrophages in Glioblastoma: Current Therapies and Future Directions). Cancer Gene Therapy Week. September 15, 2025; p 165.
• Cancers, 2025;17(16):2687.